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a  b  s  t  r  a  c  t
Oxyntomodulin  analogues  offer  a  novel  treatment  for  obesity.  However  during  analogue  screening  in  a
rat  model  increased  food  intake  was  consistently  observed.  To further  investigate  this  ﬁnding,  a series  of
representative  analogues  (OXM14  and  OXM15)  and their  Glu-3  equivalents  (OXM14E3  and  OXM15E3)
were  administered  to  rats  for 7 days  and  food  intake and  bodyweight  measurements  taken.  To  investigate
the  role  of  glucagon  receptor  activation  glutamate  (Glu/E)  was  substituted  at amino  acid  position  3.  GLP-eywords:
xyntomodulin
lucagon
LP-1
AMP
1 and  glucagon  receptor  efﬁcacy  of  the oxyntomodulin  analogues  and  their Glu-3  counterparts  were
measured  at the  rat  receptors  in vitro.  Doses  of 25 n  mol/kg  of  OXM14  and  OXM15  increased  food  intake
by  up  to 20%.  Bodyweight  was  not  signiﬁcantly  increased.  Food  intake  was  not increased  with  the  Glu-3
peptides,  indicating  that a glucagon  receptor  mechanism  may  be  responsible  for the  increase  in  food
intake.
© 2015  The  Authors.  Published  by  Elsevier  Inc. This  is  an open  access  article  under  the  CC  BY  license. Introduction
Oxyntomodulin is the 29 amino acids of glucagon with an addi-
ional C-terminal octapeptide tail. It is a product of the proglucagon
recursor peptide along with glucagon-like peptide-1 (GLP-1),
lucagon and glucagon-like peptide-2 (GLP-2) and is co-secreted
ost prandially with GLP-1 from L-cells in the distal intestine [21]. A
peciﬁc oxyntomodulin receptor has not been identiﬁed; the pep-
ides proposed mechanism of action is by activation of both the
lucagon and GLP-1 receptors, although with reduced efﬁcacy com-
ared to the native ligands [22,23,32]. In vivo studies have shown
hat peripheral administration of oxyntomodulin causes weight
oss in rodents [1,5,6,25] and humans [4,36,37] and both glucagon
nd oxyntomodulin have been shown to increase energy expendi-
ure in these species [7,19,34,36,37]. Based on ﬁndings in mice it has
een suggested that oxyntomodulin reduces food intake via activ-
ty at the GLP-1 receptor, while its activity at the glucagon receptor
auses weight loss by increasing energy expenditure [25]. Glucagon
timulates glycogenolysis and gluconeogenesis, elevating blood
lucose, and administration of glucagon causes hyperglycaemia [3].
owever, oxyntomodulin administration does not elevate blood
lucose [36,37]. Recent studies have suggested that chronic oxynto-
Abbreviations: Gcgr, glucagon receptor; GLP-1r, GLP-1 receptor.
∗ Corresponding author at: Department of Investigative Medicine,
mperial College London, Du Cane Road, London W12  0NN, United Kingdom.
ax: +44 0208 383 8320.
E-mail address: s.bloom@imperial.ac.uk (S.R. Bloom).
ttp://dx.doi.org/10.1016/j.peptides.2015.09.006
196-9781/© 2015 The Authors. Published by Elsevier Inc. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
modulin administration improves glucose tolerance by increasing
insulin secretion via the GLP-1 receptor and additionally by reduc-
ing weight [12,25].
Despite the beneﬁcial effects of oxyntomodulin on weight and
glucose homeostasis, the very short half-life of native oxyntomod-
ulin means it is not used therapeutically [24]. The proglucagon
peptides, for example, are susceptible to degradation by the
enzyme dipetidylpeptidase-IV (DPPIV) [39]. Our group, and several
others, have reported that oxyntomodulin can be successfully mod-
iﬁed to produce long acting analogues with sustained food intake
reduction and enhanced body weight loss [2,11,23,26].
As part of a proprietary drug development program, analogues
of oxyntomodulin were designed with modiﬁcations in regions sus-
ceptible to degradation. The changes made were conservative, thus
the analogues were not derivatized, were of similar length to the
native peptide, had no cross linkages and included only natural
amino acids. All analogues were based on the 29 amino acids of
glucagon and contained 5–7 single substitutions between residues
12–29, with 2 or 3 additional amino acid residues at the C-terminal.
During screening it was observed that when administered to rats,
the numerous analogues tested did cause signiﬁcant reductions in
bodyweight but, unexpectedly had either no effect on food intake,
or actually caused an increase. The current paper focuses on a rep-
resentative sample of these oxyntomodulin analogues to further
investigate the mechanism behind the increase in food intake and
to assess the impact these ﬁndings might have on the design and
therapeutic use of oxyntomodulin analogues.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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. Materials and methods
.1. Peptides
All oxyntomodulin analogues tested (OXM8, OXM9, OXM10,
XM14, OXM15, OXM14E3, OXM15E3) and native peptides
Exendin-4 and human glucagon, GLP-1(7-36NH2) and oxynto-
odulin) were custom synthesized by Insight Biotechnology
imited (Middlesex, UK) using solid phase peptide synthesis (SPPS)
ethodology and puriﬁed by reverse-phase preparative HPLC.
eptide purity was determined by reverse-phase HPLC and by
atrix-assisted laser desorption ionization mass spectroscopy
MALDIMS). All peptides had a purity of >90%.
.2. In vitro cAMP accumulation
The effects of oxyntomodulin analogues and native GLP-1,
lucagon and oxyntomodulin on cyclic adenosine monophosphate
cAMP) accumulation were assessed in Chinese hamster ovary
CHO-K1) cells over-expressing the rat glucagon receptor (cDNA
rom Origene, Maryland, USA) and Chinese hamster lung (CHL) cells
ver-expressing the rat GLP-1 receptor (a kind gift from Professor
ernard Thorens, University of Lausanne, Switzerland). For cAMP
tudies, cells were seeded at a density of 150000 cells/ml in a 48
ell plate (Nunc, VWR  International Inc., Chicago, USA) and incu-
ated for 24 h. Cells were serum starved for 1 h and then incubated
or 30 mins at room temperature with a range of peptide con-
entrations diluted in serum free DMEM (Sigma–Aldrich, Dorset,
K) in the presence of 1 mM IBMX (3-isobutyl-1-methylxanthine,
igma–Aldrich). After incubation, medium was removed and cells
ysed with 0.1 M HCl +0.5% Triton-X. cAMP levels were measured
sing an ELISA kit according to manufacturer’s instructions (ADI-
00-066, Enzo Life Sciences, New York, USA), optical density was
ead at 405 nm on a Biotek ELx808 (Wolf Laboratories, York, UK).
C50’s were calculated using Prism v5 (GraphPad Software Inc., San
iego, CA, USA). Concentrations were applied in duplicate or tripli-
ate per experiment and each experiment repeated a minimum of
 times.
.3. Animals
Male Wistar rats (Charles River, Margate, UK) were maintained
n individual cages under controlled temperature (21–23 ◦C) and
ight conditions (12:12 light–dark cycle, lights on at 0700 h) with
d-libitum access to food (RM1 diet; SDS, Witham, UK) and water
nless otherwise stated. All animal procedures were approved
nder the British Home Ofﬁce Animals (Scientiﬁc Procedures) Act
986 (Project License 70/7236).
.4. Seven day food intake and bodyweight studies
Rats were weighed at 09:00 on the morning of study com-
encement and randomisation to treatment groups was  stratiﬁed
y bodyweight. A subcutaneous injection of vehicle (diluent) or
eptide (maximum volume 100 l/kg, reconstituted in ZnCl2 slow
elease formulation) was administered at 1600 h daily and food and
odyweight measured at the time of administration. A minimum of
 animals per group was required based on previous observations.
 numbers varied between experiments, see ﬁgure legends for the
xact sample size of each group.
.5. Statistical analysisAll food and bodyweight data are presented as mean ± SEM.
ata was normally distributed according to the D’Agostino & Pear-
on omnibus normality test or the Shaprio–Wilk normality test for73 (2015) 95–100
groups where n = 7. Between group variances were similar accord-
ing to Bartlett’s test for equal variances. Differences in 0–7 days
cumulative food intake and bodyweight data were analysed using
one way  ANOVA and post hoc tests with Dunnett’s or Bonferroni
corrections for multiple comparisons (Prism v5, GraphPad Software
Inc. San Diego, CA, USA). cAMP EC50’s were calculated using a sig-
moidal dose response curve and non-linear regression (Prism v5).
EC50 data is presented as a ratio of analogue average EC50/average
glucagon EC50 or GLP-1 EC50. Average EC50’s were calculated from
a minimum of 3 separate experiments. In all cases P < 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Oxyntomodulin and analogues favour glucagon receptor
activity at the rat receptors
At the rat receptors, oxyntomodulin and analogues showed
greater efﬁcacy at the glucagon receptor than the GLP1 receptor
(Table 1). The analogues had greater activity than oxyntomodulin
at both the rat glucagon and GLP-1 receptors. The Glu-3 peptides
OXM14E3 and OXM15E3 had similar efﬁcacy at the rat GLP-1 recep-
tor compared to OXM14 and OXM15 respectively, however their
efﬁcacies at the rat glucagon receptor were 165 and 27 fold lower
respectively (Table 1).
3.2. Oxyntomodulin analogues reduce bodyweight without
reducing food intake
A daily dose of 25 n mol/kg OXM15 caused a signiﬁcant 17%
increase in cumulative food intake by the end of the 7 day treatment
period compared to vehicle controls (P < 0.001; n = 7–8; Fig. 1A).
Daily administration of 25 n mol/kg OXM8, OXM9 and OXM10,
signiﬁcantly reduced 7 day bodyweight by 4–6% compared to vehi-
cle controls (OXM8: P < 0.01, OXM9: P < 0.001, OXM10: P < 0.001;
n = 7–8; Fig. 1B).
Seven day food intake was  signiﬁcantly increased in all groups
administered daily 25 n mol/kg doses of OXM analogues compared
to 5 n mol/kg Exendin-4 (P < 0.001; Fig. 1A).
3.3. Lower doses of OXM14 and OXM15 reduce weight gain
without decreasing food intake
There was a dose dependent decrease in bodyweight during 7
day administration of OXM15 and similar analogue OXM14. There
was trend towards a dose dependent increase in food intake with
lower doses of both OXM14 and OXM15 compared to vehicle con-
trols. Doses of 12-, 25- and 50 n mol/kg of OXM14 non signiﬁcantly
increased food intake by 5%, 11% and 12% respectively compared
to vehicle controls (Fig. 2A). A daily 100 n mol/kg dose of OXM14
signiﬁcantly decreased food intake by 23% compared to vehicle con-
trols (P < 0.05, Fig. 2A). Doses of 12- and 25 n mol/kg decreased 7 day
bodyweight non signiﬁcantly by 1.2% and 1.7% respectively com-
pared to vehicle controls. Doses of 50 n mol/kg and 100 n mol/kg of
OXM14 signiﬁcantly decreased bodyweight by 5% and 12% respec-
tively compared to controls (P < 0.05, P < 0.001; n = 8–9; Fig. 2B).
Doses of 10-, 15- and 25 n mol/kg of OXM15 increased 7 day food
intake by 4%, 5% and 8% respectively compared to vehicle controls.
A daily 50 n mol/kg dose of OXM15 non signiﬁcantly decreased food
intake by 12% compared to controls (Fig. 3A). Seven day bodyweight
was non signiﬁcantly decreased by 1.4% by daily administration
of 25 n mol/kg OXM15 (Fig. 3B). Daily doses of 35 n mol/kg and
50 n mol/kg OXM15 signiﬁcantly reduced 7 day bodyweight by
5% and 8% respectively compared to controls (P < 0.001; n = 9–10;
Fig. 3B).
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Table  1
cAMP EC50 ratios.
EC50 ± SEM (nM) EC50 ratio to native peptide (arbitrary units)
Rat Gcgr Rat GLP-1r Rat Gcgr Rat GLP-1r
GLP-1 >1000 0.08 ± 0.01 ND 1.0
Exendin-4 >1000 0.06 ± 0.01 ND 0.75
Glucagon 0.34 ± 0.04 23.4 ± 5.88 1.0 297.2
OXM  11.4 ± 2.81 9.10 ± 0.40 33.1 115.7
OXM8  0.21 ± 0.05 2.18 ± 0.43 1.2 13.7
OXM9  0.48 ± 0.11 4.38 ± 0.81 0.6 27.7
OXM10 0.40 ± 0.10 1.08 ± 0.15 1.4 55.7
OXM15 0.38 ± 0.09 4.39 ± 1.17 1.1 55.8
OXM15E3 10.1 ± 1.66 6.99 ± 0.29 29.3 88.9
OXM14 0.23 ± 0.03 1.49 ± 0.25 0.7 19.0
OXM14E3 39.9 ± 2.61 2.18 ± 0.06 115.8 27.7
EC50 values for cAMP accumulation measured in CHO-K1 cells over expressing the rat glucagon receptor, or CHL cells over expressing the rat GLP-1 receptor after 30 min
peptide stimulation. EC50’s for each peptide were calculated from the average EC50’s from 3–5 independent experiments. Receptor efﬁcacy at the rat glucagon receptor is
also  expressed as a ratio of the EC50 of glucagon and of the EC50 of GLP1 at the rat GLP-1 receptor. A ratio value below 1 indicates enhanced efﬁcacy, and above 1 decreased
efﬁcacy  compared to the native peptide. ND—not determined, OXM—oxyntomodulin, Gcgr—glucagon receptor, GLP-1r—GLP-1 receptor.
Fig. 1. Daily S/C 25 n mol/kg oxyntomodulin analogue administration increased cumulative 7 day food intake (A) and reduced bodyweight (B) compared to vehicle admin-
istration. Average starting weight 506 g. Vehicle, OXM9, OXM10 n = 8/group; all other groups n = 7/group. Data represent mean ± SEM. Signiﬁcance calculated using one way
ANOVA (A, F = 16.78, P < 0.0001; B, F = 5.074, P = 0.0011) with Bonferroni post hoc test (*P < 0.05, ***P < 0.001 vs vehicle controls, ###P < 0.001 vs Exendin-4 group).
Fig. 2. Cumulative 7 day food intake (A) and body weight change (B) in response to daily SC injections of various doses of OXM14 or vehicle. Average starting weight 577 g.
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tehicle  n = 9/group; all other groups n = 8/group. Data represent mean ± SEM. Sign
ith  Dunnett’s post hoc test (*P < 0.05, ***P < 0.001 vs vehicle controls).
.4. No increased food intake with reduced glucagon receptor
ctivity
To further investigate the effects of glucagon receptor activity
n food intake, OXM14 and OXM15 were re-synthesized with the
osition 3 glutamine (Gln/Q) substituted for glutamate (Glu/E). This
ubstitution had previously been reported to signiﬁcantly dimin-
sh glucagon receptor activity without affecting GLP-1 receptor
ctivity [12]. In-line with previous ﬁndings using Glu-3 pep-
ides, the efﬁcacy of OXM14E3 and OXM15E3 at the glucagone calculated using one way ANOVA (A, F = 4.64, P = 0.0018; B, F = 13.58, P < 0.0001)
receptor were 173 and 27 times lower compared to OXM14 and
OXM15 respectively, while their GLP1r activity was  unaffected
(Table 1).
As seen in the previous experiments; repeated daily
administration of 25 n mol/kg OXM15 signiﬁcantly increased
cumulative food intake over 7 days by 20% (P < 0.01), and
OXM14 increased cumulative food intake by 19% (P < 0.05;
n = 7; Fig. 4).
Neither OXM14E3 or OXM15E3 signiﬁcantly increased cumula-
tive food intake compared to vehicle controls (Fig. 4).
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Fig. 3. Cumulative 7 day food intake (A) and bodyweight change (B) after daily administr
OXM(10) n = 9/group; all other groups n = 10/group. Data represent mean ± SEM. Signiﬁcan
with  Dunnett’s post hoc test (***P < 0.001 vs vehicle controls).
Fig. 4. Cumulative 7 day food intake in response to daily 25 n mol/kg SC injections
of  OXM14, OXM14E3, OXM15, OXM15E3 or vehicle. Vehicle n = 8/group; all other
groups n = 7. Data represent mean ± SEM. Signiﬁcance calculated using one way
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the importance of testing in more than one model, particularly forNOVA (F = 5.258, P = 0.0029) with Dunnett’s post hoc test (*P < 0.05, **P < 0.01 vs
ehicle controls).
. Discussion
This study suggests that analogues of oxyntomodulin can cause
n increase in food intake in rats while generating signiﬁcant reduc-
ions in bodyweight, and that the increased consumption may
nvolve a glucagon receptor mediated mechanism. This ﬁnding
eems to be a rat speciﬁc phenomenon which may  be of interest
n the development of oxyntomodulin analogues for therapeutic
reatment of obesity in humans.
Previous studies have reported the use of oxyntomodulin ana-
ogues with a glutamate at amino acid position 3 as a tool to
nvestigate the contribution of glucagon receptor activity to the
ffects on food intake and bodyweight. Thus, changing the posi-
ion 3 glutamine of oxyntomodulin to glutamate (as found in GLP-1
nd its natural analogue exendin-4) severely diminishes glucagon
eceptor activity without affecting the activity at the GLP-1 recep-
or, essentially producing a GLP-1 receptor selective analogue
12,25,31]. Comparing the effects of oxyntomodulin analogues
ith their Glu-3 counterparts in a chronic study therefore enables
nvestigation of the contribution of glucagon receptor activity to
xyntomodulin function. In the current study, no increase in food
ntake was seen with GLP-1 selective Glu-3 analogues OXM14E3
nd OXM15E3, suggesting that a glucagon receptor mechanism
ay  be involved in mediating the increase in food intake. An
ncrease in energy expenditure is seen following peripheral admin-
stration of glucagon in rodents [8] and humans [34]. Therefore
n the current study the increase in food intake may  be a com-
ensatory response to a chronic increase in energy expenditure.
 similar pattern of increased food intake without an increase ination of OXM15 at various doses. Average starting weight 542 g. Vehicle, OXM(50),
ce calculated using one way ANOVA (A, F = 3.503, P = 0.0089; B, F = 27.13, P < 0.0001)
bodyweight is observed in patients with thyrotoxicosis and this is
generally accepted to be a compensatory response to the hyper-
metabolic state induced by high levels of thyroid hormone [13].
A previous study has reported an acute hyperphagic response to
IP glucagon administration in rats [18] and they attributed this to
the low dose of 50 g/kg (14 n mol/kg) that was used. Although
glucagon has been suggested to acutely reduce food intake, this
is typically observed following administration of higher doses
[15,17,20,30]. Also, several studies that have reported an acute
reduction in food intake administered glucagon directly into the
portal circulation [14,16,29,35]. This could have produced different
effects on food intake as it would have resulted in high glucagon
levels local to the liver and could be considered less physiological
than peripheral administration. No previous studies have inves-
tigated the effects of chronic exposure to glucagon on rodent food
intake, probably due to the difﬁculties imposed by glucagon’s short
half-life.
Previous studies using native oxyntomodulin and longer last-
ing dual analogues have reported a reduction in food intake after
repeated peripheral administration in rodents [6,9,10,23,26,31]
and humans [36,37]. The range of OXM14 and OXM15 doses that
increase food intake are quite narrow and are generally lower than
the doses of 50 n mol/kg [6], 1100 n mol/kg [25] and 1400 n mol/kg
[23] of oxyntomodulin used in several prior chronic studies. Addi-
tionally, methods of peptide administration differ: some studies
infused peptides [25] while others administered peptide every 2–4
days [9,31] or twice daily [6,28]. Liu et al. [26] did administer their
dual analogue to rats at lower doses of 5 n mol/kg and 20 n mol/kg.
However, their particular analogue had a much greater efﬁcacy at
the GLP-1 receptor, compared to the oxyntomodulin analogues in
the current study, therefore any potential increase in food intake
could have been masked by enhanced GLP-1 receptor activity caus-
ing a dominant reduction in food intake. Both native glucagon
and oxyntomodulin have short half-lives and are also unstable in
solution which makes it difﬁcult to study the effects of chronic
administration; Alzet pumps are problematic and frequent injec-
tions would involve signiﬁcant handling and consequential animal
stress.
Interestingly, the increase in food intake with low doses of
oxyntomodulin analogues was not replicated in a mouse model
(unpublished observations), indicating that this could be a species
speciﬁc effect. A number of previous studies with oxyntomod-
ulin analogues have been carried out using only mouse models
[9,23,27,28,31], but there is no evidence as to whether human
responses are more similar to rats or mice. These ﬁndings highlightdual analogues where differential efﬁcacy may  occur.
Oxyntomodulin activates both the human glucagon receptor
and GLP-1 receptor with reduced efﬁcacy compared to the native
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eptides [22,23,32]. There is a paucity of information in pub-
ished literature comparing native oxyntomodulin activity at the
at glucagon receptor and rat GLP-1 receptor. Similar to previ-
us ﬁndings at the human [23] and mouse [25] receptors, we
bserved that oxyntomodulin activity at the rat receptors favoured
lucagon receptor activity. The oxyntomodulin analogues studied
n the current paper also favoured glucagon receptor activity, but
ith greater efﬁcacy at both rat receptors compared to native oxyn-
omodulin.
There was a trend towards an increase in food intake with low
oses of both analogues up to a ‘threshold dose’, beyond which food
ntake was then decreased. It could be postulated that the threshold
oint may  reﬂect the dose at which there is sufﬁcient GLP1r activity
o cause a reduction in food intake. There is a difference in threshold
ose between OXM14 and OXM15 with a higher dose of OXM14
equired to cause a reduction in food intake. It is likely this can be
ttributed to differences in their ratio of rat GLP-1 receptor to rat
lucagon receptor activity. However, OXM14 has a greater efﬁcacy
t the rat GLP-1 receptor than OXM15 which would suggest a lower
ose would be required to reduce food intake, thus highlighting the
ikelihood of a complex underlying interaction.
Exendin-4 is a naturally occurring GLP-1 receptor selective
gonist with a longer half-life. The weight loss caused by admin-
stration of this peptide in standard chow fed animals is thought
o be mainly due to reduction in food intake [33,38]. In the ini-
ial experiment, all groups administered oxyntomodulin analogues
ost similar amounts of weight as the exendin-4 group despite
ating signiﬁcantly more food. This indicates that the weight loss
aused by the oxyntomodulin analogues may  be due to increased
nergy expenditure as a result of glucagon receptor activity. With
oth OXM14 and OXM15 there was a trend towards a dose depen-
ent reduction in bodyweight. At lower doses, food intake tended
o increase as bodyweight decreased; indicating that below the
threshold point’ bodyweight loss is likely to be due to this proposed
ncreased energy expenditure mediated via glucagon receptor
ctivity. OXM15 has a similar ratio of activity at the rat glucagon
eceptor and rat GLP-1 receptor as OXM10 as well as a similar
harmacokinetic proﬁle; however OXM15 signiﬁcantly increased
ood intake despite generating less weight loss than OXM10. This
uggests that the underlying receptor interactions involved with
xyntomodulin-like dual analogues, and probably oxyntomodulin,
re complex and could include the degree of access to CNS appetite
nd energy expenditure controlling centres. Co-administration of
lucagon and GLP-1 in rodents [30] and man  [3] appears to produce
ynergistic effects on food intake, indicating probable interaction
f the two peptides.
. Conclusion
We  have shown that in a rat model low doses of oxyntomodulin
nalogues often tend to increase food intake without increasing
odyweight.. Results with GLP-1 receptor selective Glu-3 analogues
uggest that a glucagon receptor mediated mechanism may  be
nvolved in the increase in food intake. It is possible that the
ncrease in food intake may  be a compensatory response to an
ncrease in energy expenditure mediated by glucagon receptor
ctivity. It is currently unclear what impact these ﬁndings may  have
n the use of oxyntomodulin analogues in a clinical setting. Nau-
ea limits the dose of GLP-1 analogues that can be used in man.
t is unlikely that nausea is a feature of the oxyntomodulin ana-
ogues studied here, given the increase in food intake; however
 conditioned taste aversion study in rats would help to clarify
his.
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Glossary
Hyperglycaemia: High blood sugar
Hyperphagic: Increases food intakeGlycogenolysis: The breakdown of glycogen stores to produce glucose
